Abstract
R isperidone is expensive but, apparently, not too expensive. Recent Canadian guidelines suggest a cut-off point for how much spending can be justified per quality-adjusted life-year (QALY) gained when comparing old treatments with new. And a recent cost-utility study conducted by Janssen researchers has determined that risperidone comes close enough to this cut-off point to be recommended as treatment for schizophrenia. The results of this study were discussed at the 20th Annual Canadian Society of Hospital Pharmacists (Western Branches) [ Banff, Alberta, Canada; March 1994 ].
This is a preview of subscription content, log in via an institution to check access.
Rights and permissions
About this article
Cite this article
Plosker, G.L. Risperidone. Pharmacoecon. Outcomes News 3, 8–9 (1994). https://doi.org/10.1007/BF03289641
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03289641